Lumito expands commercial reach through partnership with Aurevia
Swedish Lumito has signed a collaboration with CRO firm Aurevia to promote its SCIZYS tissue analysis technology to drug development clients.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, Swedish company Lumito AB has entered a collaboration with Aurevia AB, a CRO firm specialising in clinical research and regulatory services. The partnership gives Lumito another channel for reaching customers in drug development and clinical research, while Aurevia can widen its offering with the SCIZYS platform for advanced tissue analysis.
SCIZYS, built on patented upconverting nanoparticles, detects and quantifies specific proteins in tissue samples with very high sensitivity. The companies have already discussed possible areas of application, and earlier this spring Aurevia hosted a breast cancer seminar at Uppsala University Hospital where Lumito was the only invited presenting company.
why it matters
This is a corporate update about a small company whose shares trade on NGM Growth Market. It is unlikely to move the broader market, since it concerns expanding sales channels and includes no financial figures.
tags
instruments
sources
- Lumito strengthens its commercial position through partnership with Aurevia in advanced tissue analysis — TradingView, 22 October 2026 at 07:40 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗